Solana Company

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, HSDT is priced at $2.31, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, HSDT's ROE is -1.55%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, HSDT is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BSX-PA's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ISRG has a market cap of 159B. Regarding current trading prices, HSDT is priced at $2.31, while ISRG trades at $449.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ISRG's P/E ratio is 54.69. In terms of profitability, HSDT's ROE is -1.55%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, HSDT is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ISRG's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ABT has a market cap of 153.9B. Regarding current trading prices, HSDT is priced at $2.31, while ABT trades at $88.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ABT's P/E ratio is 24.75. In terms of profitability, HSDT's ROE is -1.55%, compared to ABT's ROE of +0.12%. Regarding short-term risk, HSDT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ABT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SYK has a market cap of 123.2B. Regarding current trading prices, HSDT is priced at $2.31, while SYK trades at $321.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SYK's P/E ratio is 36.40. In terms of profitability, HSDT's ROE is -1.55%, compared to SYK's ROE of +0.15%. Regarding short-term risk, HSDT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SYK's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, MDT has a market cap of 100.3B. Regarding current trading prices, HSDT is priced at $2.31, while MDT trades at $78.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas MDT's P/E ratio is 21.83. In terms of profitability, HSDT's ROE is -1.55%, compared to MDT's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check MDT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BSX has a market cap of 84.2B. Regarding current trading prices, HSDT is priced at $2.31, while BSX trades at $56.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BSX's P/E ratio is 22.31. In terms of profitability, HSDT's ROE is -1.55%, compared to BSX's ROE of +0.15%. Regarding short-term risk, HSDT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BSX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BRKRP has a market cap of 51.3B. Regarding current trading prices, HSDT is priced at $2.31, while BRKRP trades at $337.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BRKRP's P/E ratio is N/A. In terms of profitability, HSDT's ROE is -1.55%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, HSDT is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BRKRP's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, EW has a market cap of 47.8B. Regarding current trading prices, HSDT is priced at $2.31, while EW trades at $82.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas EW's P/E ratio is 44.85. In terms of profitability, HSDT's ROE is -1.55%, compared to EW's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check EW's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, RMD has a market cap of 30.4B. Regarding current trading prices, HSDT is priced at $2.31, while RMD trades at $209.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas RMD's P/E ratio is 20.23. In terms of profitability, HSDT's ROE is -1.55%, compared to RMD's ROE of +0.24%. Regarding short-term risk, HSDT is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check RMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, DXCM has a market cap of 27.6B. Regarding current trading prices, HSDT is priced at $2.31, while DXCM trades at $71.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas DXCM's P/E ratio is 30.66. In terms of profitability, HSDT's ROE is -1.55%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, HSDT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check DXCM's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PHG has a market cap of 25.4B. Regarding current trading prices, HSDT is priced at $2.31, while PHG trades at $26.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PHG's P/E ratio is 23.04. In terms of profitability, HSDT's ROE is -1.55%, compared to PHG's ROE of +0.09%. Regarding short-term risk, HSDT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PHG's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, STE has a market cap of 21.2B. Regarding current trading prices, HSDT is priced at $2.31, while STE trades at $215.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas STE's P/E ratio is 27.24. In terms of profitability, HSDT's ROE is -1.55%, compared to STE's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check STE's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, HSDT is priced at $2.31, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ABMD's P/E ratio is 65.36. In terms of profitability, HSDT's ROE is -1.55%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ABMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ZBH has a market cap of 16.5B. Regarding current trading prices, HSDT is priced at $2.31, while ZBH trades at $85.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ZBH's P/E ratio is 22.12. In terms of profitability, HSDT's ROE is -1.55%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, HSDT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ZBH's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, HSDT is priced at $2.31, while SNN trades at $31.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SNN's P/E ratio is 21.69. In terms of profitability, HSDT's ROE is -1.55%, compared to SNN's ROE of +0.12%. Regarding short-term risk, HSDT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SNN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, HSDT is priced at $2.31, while PEN trades at $327.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PEN's P/E ratio is 75.43. In terms of profitability, HSDT's ROE is -1.55%, compared to PEN's ROE of +0.12%. Regarding short-term risk, HSDT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PEN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, HSDT is priced at $2.31, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SWAV's P/E ratio is 78.76. In terms of profitability, HSDT's ROE is -1.55%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, HSDT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SWAV's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ALGN has a market cap of 11.7B. Regarding current trading prices, HSDT is priced at $2.31, while ALGN trades at $163.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ALGN's P/E ratio is 27.51. In terms of profitability, HSDT's ROE is -1.55%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ALGN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, GMED has a market cap of 11.3B. Regarding current trading prices, HSDT is priced at $2.31, while GMED trades at $84.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas GMED's P/E ratio is 19.63. In terms of profitability, HSDT's ROE is -1.55%, compared to GMED's ROE of +0.13%. Regarding short-term risk, HSDT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check GMED's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PODD has a market cap of 10.8B. Regarding current trading prices, HSDT is priced at $2.31, while PODD trades at $156.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PODD's P/E ratio is 36.59. In terms of profitability, HSDT's ROE is -1.55%, compared to PODD's ROE of +0.21%. Regarding short-term risk, HSDT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PODD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, HSDT is priced at $2.31, while MASI trades at $178.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas MASI's P/E ratio is 44.25. In terms of profitability, HSDT's ROE is -1.55%, compared to MASI's ROE of +0.09%. Regarding short-term risk, HSDT is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check MASI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, GKOS has a market cap of 8.4B. Regarding current trading prices, HSDT is priced at $2.31, while GKOS trades at $143.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas GKOS's P/E ratio is -43.56. In terms of profitability, HSDT's ROE is -1.55%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, HSDT is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check GKOS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, HSDT is priced at $2.31, while BIO trades at $287.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BIO's P/E ratio is 47.94. In terms of profitability, HSDT's ROE is -1.55%, compared to BIO's ROE of +0.02%. Regarding short-term risk, HSDT is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BIO's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, HSDT is priced at $2.31, while BIO-B trades at $276.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BIO-B's P/E ratio is 46.10. In terms of profitability, HSDT's ROE is -1.55%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, HSDT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BIO-B's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BRKR has a market cap of 6.7B. Regarding current trading prices, HSDT is priced at $2.31, while BRKR trades at $44.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BRKR's P/E ratio is -184.42. In terms of profitability, HSDT's ROE is -1.55%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, HSDT is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BRKR's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, HSDT is priced at $2.31, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas NARI's P/E ratio is -59.24. In terms of profitability, HSDT's ROE is -1.55%, compared to NARI's ROE of -0.00%. Regarding short-term risk, HSDT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check NARI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, HSDT is priced at $2.31, while LIVN trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas LIVN's P/E ratio is 37.61. In terms of profitability, HSDT's ROE is -1.55%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, HSDT is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check LIVN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, HSDT is priced at $2.31, while IRTC trades at $117.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas IRTC's P/E ratio is -136.05. In terms of profitability, HSDT's ROE is -1.55%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check IRTC's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, HSDT is priced at $2.31, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AXNX's P/E ratio is -709.80. In terms of profitability, HSDT's ROE is -1.55%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, HSDT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AXNX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, HSDT is priced at $2.31, while ITGR trades at $91.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ITGR's P/E ratio is 22.70. In terms of profitability, HSDT's ROE is -1.55%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, HSDT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ITGR's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, HSDT is priced at $2.31, while TMDX trades at $68.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas TMDX's P/E ratio is 15.54. In terms of profitability, HSDT's ROE is -1.55%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, HSDT is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check TMDX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, HSDT is priced at $2.31, while AXGN trades at $42.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AXGN's P/E ratio is -66.70. In terms of profitability, HSDT's ROE is -1.55%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AXGN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, HSDT is priced at $2.31, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas NUVA's P/E ratio is 75.00. In terms of profitability, HSDT's ROE is -1.55%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, HSDT is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check NUVA's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, HSDT is priced at $2.31, while ESTA trades at $70.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ESTA's P/E ratio is -47.65. In terms of profitability, HSDT's ROE is -1.55%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, HSDT is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ESTA's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, HSDT is priced at $2.31, while UFPT trades at $224.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas UFPT's P/E ratio is 25.62. In terms of profitability, HSDT's ROE is -1.55%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, HSDT is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check UFPT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, HSDT is priced at $2.31, while PRCT trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PRCT's P/E ratio is -15.36. In terms of profitability, HSDT's ROE is -1.55%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, HSDT is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PRCT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, HSDT is priced at $2.31, while ENOV trades at $26.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ENOV's P/E ratio is -1.33. In terms of profitability, HSDT's ROE is -1.55%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, HSDT is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ENOV's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, HSDT is priced at $2.31, while AHCO trades at $10.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AHCO's P/E ratio is -17.76. In terms of profitability, HSDT's ROE is -1.55%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, HSDT is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AHCO's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $2.31, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas HSKA's P/E ratio is -62.49. In terms of profitability, HSDT's ROE is -1.55%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, HSDT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check HSKA's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $2.31, while INSP trades at $44.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas INSP's P/E ratio is 10.03. In terms of profitability, HSDT's ROE is -1.55%, compared to INSP's ROE of +0.18%. Regarding short-term risk, HSDT is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check INSP's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $2.31, while ATEC trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ATEC's P/E ratio is -9.92. In terms of profitability, HSDT's ROE is -1.55%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, HSDT is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ATEC's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, HSDT is priced at $2.31, while IART trades at $15.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas IART's P/E ratio is -2.38. In terms of profitability, HSDT's ROE is -1.55%, compared to IART's ROE of -0.48%. Regarding short-term risk, HSDT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check IART's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, HSDT is priced at $2.31, while AVNS trades at $24.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AVNS's P/E ratio is -15.46. In terms of profitability, HSDT's ROE is -1.55%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, HSDT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AVNS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, HSDT is priced at $2.31, while IRMD trades at $90.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas IRMD's P/E ratio is 49.40. In terms of profitability, HSDT's ROE is -1.55%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, HSDT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check IRMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $2.31, while BFLY trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BFLY's P/E ratio is -14.63. In terms of profitability, HSDT's ROE is -1.55%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, HSDT is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BFLY's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $2.31, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SILK's P/E ratio is -18.96. In terms of profitability, HSDT's ROE is -1.55%, compared to SILK's ROE of -0.35%. Regarding short-term risk, HSDT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SILK's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $2.31, while CNMD trades at $37.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CNMD's P/E ratio is 20.91. In terms of profitability, HSDT's ROE is -1.55%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, HSDT is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CNMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $2.31, while AORT trades at $22.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AORT's P/E ratio is 90.76. In terms of profitability, HSDT's ROE is -1.55%, compared to AORT's ROE of +0.03%. Regarding short-term risk, HSDT is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AORT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $2.31, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas FNA's P/E ratio is -19.83. In terms of profitability, HSDT's ROE is -1.55%, compared to FNA's ROE of -0.35%. Regarding short-term risk, HSDT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check FNA's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, HSDT is priced at $2.31, while TNDM trades at $15.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas TNDM's P/E ratio is -10.98. In terms of profitability, HSDT's ROE is -1.55%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, HSDT is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check TNDM's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, INMD has a market cap of 888.3M. Regarding current trading prices, HSDT is priced at $2.31, while INMD trades at $14.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas INMD's P/E ratio is 10.39. In terms of profitability, HSDT's ROE is -1.55%, compared to INMD's ROE of +0.13%. Regarding short-term risk, HSDT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check INMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, HSDT is priced at $2.31, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CSII's P/E ratio is -20.83. In terms of profitability, HSDT's ROE is -1.55%, compared to CSII's ROE of -0.14%. Regarding short-term risk, HSDT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CSII's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SSII has a market cap of 788.5M. Regarding current trading prices, HSDT is priced at $2.31, while SSII trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SSII's P/E ratio is -78.80. In terms of profitability, HSDT's ROE is -1.55%, compared to SSII's ROE of -0.23%. Regarding short-term risk, HSDT is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SSII's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BVS has a market cap of 741.2M. Regarding current trading prices, HSDT is priced at $2.31, while BVS trades at $10.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BVS's P/E ratio is 26.68. In terms of profitability, HSDT's ROE is -1.55%, compared to BVS's ROE of +0.16%. Regarding short-term risk, HSDT is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BVS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, HSDT is priced at $2.31, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CRY's P/E ratio is 425.71. In terms of profitability, HSDT's ROE is -1.55%, compared to CRY's ROE of +0.03%. Regarding short-term risk, HSDT is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CRY's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, LMRI has a market cap of 711M. Regarding current trading prices, HSDT is priced at $2.31, while LMRI trades at $7.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas LMRI's P/E ratio is -18.97. In terms of profitability, HSDT's ROE is -1.55%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, HSDT is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check LMRI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CBLL has a market cap of 686.4M. Regarding current trading prices, HSDT is priced at $2.31, while CBLL trades at $18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CBLL's P/E ratio is -11.17. In terms of profitability, HSDT's ROE is -1.55%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, HSDT is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CBLL's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SIBN has a market cap of 657.3M. Regarding current trading prices, HSDT is priced at $2.31, while SIBN trades at $14.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SIBN's P/E ratio is -38.00. In terms of profitability, HSDT's ROE is -1.55%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, HSDT is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SIBN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, HSDT is priced at $2.31, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SRDX's P/E ratio is -34.66. In terms of profitability, HSDT's ROE is -1.55%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, HSDT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SRDX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BWAY has a market cap of 599.3M. Regarding current trading prices, HSDT is priced at $2.31, while BWAY trades at $15.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BWAY's P/E ratio is 84.89. In terms of profitability, HSDT's ROE is -1.55%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check BWAY's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, HSDT is priced at $2.31, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas APEN's P/E ratio is -9.43. In terms of profitability, HSDT's ROE is -1.55%, compared to APEN's ROE of -0.85%. Regarding short-term risk, HSDT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check APEN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, TCMD has a market cap of 560.3M. Regarding current trading prices, HSDT is priced at $2.31, while TCMD trades at $24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas TCMD's P/E ratio is 28.55. In terms of profitability, HSDT's ROE is -1.55%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check TCMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, NPCE has a market cap of 554.7M. Regarding current trading prices, HSDT is priced at $2.31, while NPCE trades at $16.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas NPCE's P/E ratio is -25.03. In terms of profitability, HSDT's ROE is -1.55%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, HSDT is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check NPCE's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CERS has a market cap of 539M. Regarding current trading prices, HSDT is priced at $2.31, while CERS trades at $2.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CERS's P/E ratio is -53.80. In terms of profitability, HSDT's ROE is -1.55%, compared to CERS's ROE of -0.15%. Regarding short-term risk, HSDT is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CERS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, HSDT is priced at $2.31, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, HSDT's ROE is -1.55%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, HSDT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ZIMV's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, OFIX has a market cap of 491.1M. Regarding current trading prices, HSDT is priced at $2.31, while OFIX trades at $12.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas OFIX's P/E ratio is -8.10. In terms of profitability, HSDT's ROE is -1.55%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, HSDT is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check OFIX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CTKB has a market cap of 486.9M. Regarding current trading prices, HSDT is priced at $2.31, while CTKB trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CTKB's P/E ratio is -6.50. In terms of profitability, HSDT's ROE is -1.55%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CTKB's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, KIDS has a market cap of 475.2M. Regarding current trading prices, HSDT is priced at $2.31, while KIDS trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas KIDS's P/E ratio is -11.01. In terms of profitability, HSDT's ROE is -1.55%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, HSDT is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check KIDS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, VREX has a market cap of 426.5M. Regarding current trading prices, HSDT is priced at $2.31, while VREX trades at $10.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas VREX's P/E ratio is -5.07. In terms of profitability, HSDT's ROE is -1.55%, compared to VREX's ROE of -0.18%. Regarding short-term risk, HSDT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check VREX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, LAB has a market cap of 413.8M. Regarding current trading prices, HSDT is priced at $2.31, while LAB trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas LAB's P/E ratio is -8.15. In terms of profitability, HSDT's ROE is -1.55%, compared to LAB's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check LAB's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, DCTH has a market cap of 387.7M. Regarding current trading prices, HSDT is priced at $2.31, while DCTH trades at $11.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas DCTH's P/E ratio is 1123.00. In terms of profitability, HSDT's ROE is -1.55%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, HSDT is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check DCTH's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, VMD has a market cap of 371.1M. Regarding current trading prices, HSDT is priced at $2.31, while VMD trades at $9.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas VMD's P/E ratio is 26.16. In terms of profitability, HSDT's ROE is -1.55%, compared to VMD's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check VMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PACB has a market cap of 369.6M. Regarding current trading prices, HSDT is priced at $2.31, while PACB trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PACB's P/E ratio is -2.90. In terms of profitability, HSDT's ROE is -1.55%, compared to PACB's ROE of -4.88%. Regarding short-term risk, HSDT is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PACB's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CLPT has a market cap of 335.9M. Regarding current trading prices, HSDT is priced at $2.31, while CLPT trades at $11.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CLPT's P/E ratio is -11.20. In terms of profitability, HSDT's ROE is -1.55%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, HSDT is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CLPT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, AVR has a market cap of 317.1M. Regarding current trading prices, HSDT is priced at $2.31, while AVR trades at $8.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas AVR's P/E ratio is -3.88. In terms of profitability, HSDT's ROE is -1.55%, compared to AVR's ROE of -1.24%. Regarding short-term risk, HSDT is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check AVR's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ELMD has a market cap of 311.7M. Regarding current trading prices, HSDT is priced at $2.31, while ELMD trades at $37.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ELMD's P/E ratio is 32.17. In terms of profitability, HSDT's ROE is -1.55%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, HSDT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ELMD's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, HSDT is priced at $2.31, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SMLR's P/E ratio is 3.92. In terms of profitability, HSDT's ROE is -1.55%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, HSDT is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SMLR's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CATX has a market cap of 292M. Regarding current trading prices, HSDT is priced at $2.31, while CATX trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CATX's P/E ratio is -2.68. In terms of profitability, HSDT's ROE is -1.55%, compared to CATX's ROE of -0.42%. Regarding short-term risk, HSDT is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CATX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SGHT has a market cap of 264.4M. Regarding current trading prices, HSDT is priced at $2.31, while SGHT trades at $4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SGHT's P/E ratio is -6.94. In terms of profitability, HSDT's ROE is -1.55%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, HSDT is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SGHT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, MASS has a market cap of 263.9M. Regarding current trading prices, HSDT is priced at $2.31, while MASS trades at $6.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas MASS's P/E ratio is -7.20. In terms of profitability, HSDT's ROE is -1.55%, compared to MASS's ROE of -0.26%. Regarding short-term risk, HSDT is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check MASS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, RXST has a market cap of 255M. Regarding current trading prices, HSDT is priced at $2.31, while RXST trades at $6.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas RXST's P/E ratio is -5.45. In terms of profitability, HSDT's ROE is -1.55%, compared to RXST's ROE of -0.17%. Regarding short-term risk, HSDT is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check RXST's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, HSDT is priced at $2.31, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas MGRM's P/E ratio is -11.11. In terms of profitability, HSDT's ROE is -1.55%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, HSDT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check MGRM's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PMI has a market cap of 240.2M. Regarding current trading prices, HSDT is priced at $2.31, while PMI trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PMI's P/E ratio is -0.21. In terms of profitability, HSDT's ROE is -1.55%, compared to PMI's ROE of +4.99%. Regarding short-term risk, HSDT is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.Check PMI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SENS has a market cap of 238.6M. Regarding current trading prices, HSDT is priced at $2.31, while SENS trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SENS's P/E ratio is -2.90. In terms of profitability, HSDT's ROE is -1.55%, compared to SENS's ROE of -1.30%. Regarding short-term risk, HSDT is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SENS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, HSDT is priced at $2.31, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas NVRO's P/E ratio is -1.91. In terms of profitability, HSDT's ROE is -1.55%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, HSDT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check NVRO's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, HSDT is priced at $2.31, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas EYES's P/E ratio is N/A. In terms of profitability, HSDT's ROE is -1.55%, compared to EYES's ROE of -2.64%. Regarding short-term risk, HSDT is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check EYES's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, PROF has a market cap of 209.4M. Regarding current trading prices, HSDT is priced at $2.31, while PROF trades at $6.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas PROF's P/E ratio is -5.58. In terms of profitability, HSDT's ROE is -1.55%, compared to PROF's ROE of -0.70%. Regarding short-term risk, HSDT is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check PROF's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, ANIK has a market cap of 201.2M. Regarding current trading prices, HSDT is priced at $2.31, while ANIK trades at $15.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas ANIK's P/E ratio is -19.14. In terms of profitability, HSDT's ROE is -1.55%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, HSDT is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check ANIK's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, HSDT is priced at $2.31, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas BSGM's P/E ratio is -5.81. In terms of profitability, HSDT's ROE is -1.55%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, HSDT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.Check BSGM's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, TMCI has a market cap of 182.9M. Regarding current trading prices, HSDT is priced at $2.31, while TMCI trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas TMCI's P/E ratio is -2.94. In terms of profitability, HSDT's ROE is -1.55%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, HSDT is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check TMCI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, HSDT is priced at $2.31, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas MDGS's P/E ratio is -0.27. In terms of profitability, HSDT's ROE is -1.55%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, HSDT is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.Check MDGS's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, INGN has a market cap of 171.7M. Regarding current trading prices, HSDT is priced at $2.31, while INGN trades at $6.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas INGN's P/E ratio is -6.97. In terms of profitability, HSDT's ROE is -1.55%, compared to INGN's ROE of -0.13%. Regarding short-term risk, HSDT is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check INGN's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, HSDT is priced at $2.31, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas QIPT's P/E ratio is -15.87. In terms of profitability, HSDT's ROE is -1.55%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, HSDT is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check QIPT's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, CVRX has a market cap of 160.2M. Regarding current trading prices, HSDT is priced at $2.31, while CVRX trades at $6.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas CVRX's P/E ratio is -3.01. In terms of profitability, HSDT's ROE is -1.55%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, HSDT is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check CVRX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, EDAP has a market cap of 159.3M. Regarding current trading prices, HSDT is priced at $2.31, while EDAP trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas EDAP's P/E ratio is -5.18. In terms of profitability, HSDT's ROE is -1.55%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, HSDT is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check EDAP's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, APYX has a market cap of 158.3M. Regarding current trading prices, HSDT is priced at $2.31, while APYX trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas APYX's P/E ratio is -17.18. In terms of profitability, HSDT's ROE is -1.55%, compared to APYX's ROE of -0.91%. Regarding short-term risk, HSDT is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check APYX's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, SNWV has a market cap of 144M. Regarding current trading prices, HSDT is priced at $2.31, while SNWV trades at $16.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas SNWV's P/E ratio is 17.45. In terms of profitability, HSDT's ROE is -1.55%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, HSDT is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check SNWV's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, QTI has a market cap of 137.3M. Regarding current trading prices, HSDT is priced at $2.31, while QTI trades at $5.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas QTI's P/E ratio is -4.82. In terms of profitability, HSDT's ROE is -1.55%, compared to QTI's ROE of -63.31%. Regarding short-term risk, HSDT is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check QTI's competition here

HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSDT stands at 134.9M. In comparison, NNOX has a market cap of 126M. Regarding current trading prices, HSDT is priced at $2.31, while NNOX trades at $1.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSDT currently has a P/E ratio of 0.01, whereas NNOX's P/E ratio is -1.56. In terms of profitability, HSDT's ROE is -1.55%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, HSDT is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.Check NNOX's competition here